top of page

ASGCT 2026: nChroma Bio believes that Hepatitis B is the perfect indication for its epigenetic editing platform. They are already in the clinic and will have initial data this year

  • May 14
  • 1 min read

CEO Jeff Walsh describes the concept of epigenetic editing and why the company chose Hepatitis B, and walks us through the dose escalation schedule that the trial is going through. Plus, work on a virus-like particle delivery method that the company envisions for non-liver delivery.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page